Prenetics Group (PRE) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Prenetics Group has reported a strong start to 2024 with a 30.2% increase in first-quarter revenue and a significant 159.8% rise in gross profit compared to the previous year. The company also confirmed its focus on the U.S. consumer healthcare market and reiterated its 2024 revenue forecast of $33 to $36 million. With robust financials, including $86.6 million in cash and short-term assets, Prenetics is advancing its strategic goals, including its early cancer detection venture, Insighta.
For further insights into PRE stock, check out TipRanks’ Stock Analysis page.
